C12N 2760/18862
By genetic engineering
Official title: by genetic engineering
C12N2760/18862 (By genetic engineering) appears on 0 US grants and 5 published applications in this corpus.
Search patents in C12N- Granted patents
- 0
- Published applications
- 5
- Assignees
- 3
- Inventors
- 15
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 1 |
| 2016 | 0 | 1 |
By publication year.
Recent patents
No granted patents in this class yet.
- Semi-live respiratory syncytial virus vaccine5 May 2016US 2016/0120974 A1Amvac AG
- Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector14 May 2015US 2015/0133531 A1Amvac AG
- Drug delivery vehicle for cancer therapy, process for producing the same, and pharmaceutical preparation using the same3 Nov 2011US 2011/0268769 A1
- Drug delivery vehicle for cancer therapy, process for producing the same, and pharmaceutical preparation using the same18 Dec 2008US 2008/0312130 A1Genomldea Inc.
- Paramyxovirus-derived RNP30 Jan 2003US 2003/0022376 A1
Most cited
By later US patents
No patent in this class has been cited by a later US patent yet.